{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T01:58:12Z","timestamp":1776995892905,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s13730-020-00504-7","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T07:02:51Z","timestamp":1594191771000},"page":"6-11","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Bevacizumab-associated glomerular microangiopathy that occurred after postoperative chemotherapy for ovarian cancer"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4910-0278","authenticated-orcid":false,"given":"Madoka","family":"Morimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoo","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,8]]},"reference":[{"issue":"8","key":"504_CR1","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1681\/asn.2010020167","volume":"21","author":"S Wu","year":"2010","unstructured":"Wu S, Kim C, Baer L, Zhu X. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol. 2010;21(8):1381\u20139. https:\/\/doi.org\/10.1681\/asn.2010020167.","journal-title":"J Am Soc Nephrol"},{"key":"504_CR2","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/143426","author":"H Izzedine","year":"2014","unstructured":"Izzedine H. Anti-vegf cancer therapy in nephrology practice. Int J Nephrol. 2014. https:\/\/doi.org\/10.1155\/2014\/143426.","journal-title":"Int J Nephrol."},{"key":"504_CR3","doi-asserted-by":"crossref","unstructured":"Frangi\u00e9 C, Lefaucheur C, Medioni J, Jacquot C, Hill GS, Nochy D. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. 2007. https:\/\/oncology.thelancet.comvol.","DOI":"10.1016\/S1470-2045(07)70037-2"},{"issue":"11","key":"504_CR4","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1056\/nejmoa0707330","volume":"358","author":"V Eremina","year":"2008","unstructured":"Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358(11):1129\u201336. https:\/\/doi.org\/10.1056\/nejmoa0707330.","journal-title":"N Engl J Med"},{"issue":"2","key":"504_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/ckj\/sfv139","volume":"9","author":"RM Hanna","year":"2016","unstructured":"Hanna RM, Lopez E, Wilson J, Barathan S, Cohen AH. Minimal change disease onset observed after bevacizumab administration. Clin Kidney J. 2016;9(2):239\u201344. https:\/\/doi.org\/10.1093\/ckj\/sfv139.","journal-title":"Clin Kidney J"},{"issue":"6","key":"504_CR6","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/his.13716","volume":"73","author":"F Pfister","year":"2018","unstructured":"Pfister F, Amann K, Daniel C, Klewer M, B\u00fcttner A, B\u00fcttner-Herold M. Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy. Histopathology. 2018;73(6):990\u20131001. https:\/\/doi.org\/10.1111\/his.13716.","journal-title":"Histopathology"},{"issue":"5","key":"504_CR7","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/s41379-018-0186-4","volume":"32","author":"F Person","year":"2019","unstructured":"Person F, Rinschen MM, Brix SR, et al. Bevacizumab-associated glomerular microangiopathy. Mod Pathol. 2019;32(5):684\u2013700. https:\/\/doi.org\/10.1038\/s41379-018-0186-4.","journal-title":"Mod Pathol"},{"key":"504_CR8","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/ncpneph0476","volume":"3","author":"D Roncone","year":"2007","unstructured":"Roncone D. Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma. Nat Clin Pr Nephrol. 2007;3:287.","journal-title":"Nat Clin Pr Nephrol"},{"issue":"5","key":"504_CR9","first-page":"612","volume":"56","author":"M Tomita","year":"2014","unstructured":"Tomita M, Ochiai M, Shu S, et al. A case of thrombotic microangiopathy with glomerular subendothelial IgA deposition due to bevacizumab. Jpn J Nephrol. 2014;56(5):612\u20137.","journal-title":"Jpn J Nephrol"},{"key":"504_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-6-450","author":"M Yahata","year":"2013","unstructured":"Yahata M, Nakaya I, Sakuma T, Sato H, Aoki S, Soma J. Immunoglobulin A nephropathy with massive paramesangial deposits caused by anti-vascular endothelial growth factor therapy for metastatic rectal cancer: a case report and review of the literature. BMC Res Notes. 2013. https:\/\/doi.org\/10.1186\/1756-0500-6-450.","journal-title":"BMC Res Notes."},{"issue":"2","key":"504_CR11","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1152\/ajprenal.00448.2005","volume":"291","author":"F Guan","year":"2006","unstructured":"Guan F, Villegas G, Teichman J, Mundel P, Tufro A. Autocrine VEGF\u2014a system in podocytes regulates podocin and its interaction with CD2AP. Am J Physiol - Ren Physiol. 2006;291(2):422\u20138. https:\/\/doi.org\/10.1152\/ajprenal.00448.2005.","journal-title":"Am J Physiol - Ren Physiol"},{"issue":"15","key":"504_CR12","doi-asserted-by":"publisher","first-page":"12605","DOI":"10.1074\/jbc.C300012200","volume":"278","author":"H Sugimoto","year":"2003","unstructured":"Sugimoto H, Hamanog Y, Charytan D, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem. 2003;278(15):12605\u20138. https:\/\/doi.org\/10.1074\/jbc.C300012200.","journal-title":"J Biol Chem"},{"key":"504_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-019-02558-0","author":"S Hara","year":"2019","unstructured":"Hara S, Tsuji T, Fukasawa Y, et al. Clinicopathological characteristics of thrombospondin type 1 domain-containing 7A-associated membranous nephropathy. Virchows Arch. 2019. https:\/\/doi.org\/10.1007\/s00428-019-02558-0.","journal-title":"Virchows Arch."},{"key":"504_CR14","first-page":"8675","volume":"7","author":"N Zhao","year":"2004","unstructured":"Zhao N, Xu Q, Wang M, Fei X, Pan Y, Chen X, Ma S. Mechanism of kidney injury caused by bevacizumab in rats. Int J Clin Exp Pathol. 2004;7:8675\u201383.","journal-title":"Int J Clin Exp Pathol."},{"issue":"2","key":"504_CR15","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1681\/ASN.2016010050","volume":"28","author":"E Hoxha","year":"2017","unstructured":"Hoxha E, Beck LH, Wiech T, et al. An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7a-specific antibodies in membranous nephropathy. J Am Soc Nephrol. 2017;28(2):520\u201331. https:\/\/doi.org\/10.1681\/ASN.2016010050.","journal-title":"J Am Soc Nephrol"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-020-00504-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-020-00504-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-020-00504-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T23:20:06Z","timestamp":1625700006000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-020-00504-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,8]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["504"],"URL":"https:\/\/doi.org\/10.1007\/s13730-020-00504-7","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,8]]},"assertion":[{"value":"18 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have declared that no conflict of interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from the patient in the case report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}